Evidence map›Paper›PMID 33394545›Full record

Trial reportDiabetes, obesity & metabolism2021

Interaction of diabetes genetic risk and successful lifestyle modification in the Diabetes Prevention Programme.

Sridharan Raghavan, Kathleen Jablonski, Linda M Delahanty, Nisa M Maruthur, Aaron Leong, Paul W Franks, William C Knowler, Jose C Florez, Dana Dabelea, Diabetes Prevention Program Research Group

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. MicroRNAs Associated With Incident Diabetes in the Diabetes Prevention Program.The Journal of clinical endocrinology and metabolism · 2023
    Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 2 countries.

Sridharan RaghavanMedicine Service, Department of Veterans Affairs Eastern Colorado Healthcare System, Aurora, Colorado, USA.ORCID 0000-0003-0643-4873
Kathleen JablonskiDepartment of Epidemiology and Biostatistics, Milken Institute School of Public Health, George Washington University, Washington, District of Columbia, USA.
Linda M DelahantyDiabetes Unit and Endocrine Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Nisa M MaruthurDivision of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Aaron LeongDepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Paul W FranksDepartment of Clinical Science, Genetic & Molecular Epidemiology Unit, Lund University Diabetes Centre, Malmö, Sweden.ORCID 0000-0002-0520-7604
William C KnowlerDiabetes Epidemiology and Clinical Research Section, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona, USA.
Jose C FlorezDiabetes Unit and Endocrine Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Dana DabeleaCentre for Lifecourse Epidemiology of Adiposity and Diabetes, Colorado School of Public Health, Aurora, Colorado, USA.
Diabetes Prevention Program Research Group
Harvard University · USBroad Institute · USColorado School of Public Health · USJohns Hopkins University · USLund University · SEMilken Institute · USNational Institute of Diabetes and Digestive and Kidney Diseases · USUniversity of Colorado Hospital · US

Funding

PRIMARY PREVENTION TRIAL--DATA COORDINATING CENTERU01DK048489 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI JABLONSKI, KATHLEEN ANN, TEMPROSA, MARINELLA · 1994 to 2021
$84.8M
Post-DDP Follow-up StudyU01DK048413 · NIDDK · UNIVERSITY OF WASHINGTON · PI KAHN, STEVEN EMANUEL · 1994 to 2021
$13.7M
PRIMARY PREVENTION TRIAL (DPT-2)U01DK048397 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI NATHAN, DAVID M · 1994 to 2021
$12.0M
NIDDM PRIMARY PREVENTION TRIAL (DPT 2)U01DK048404 · NIDDK · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI LAFERRERE, BLANDINE B · 1994 to 2021
$11.6M
PRIMARY PREVENTION TRIAL (DPT-2)U01DK048339 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ARANETA, MARIA ROSARIO GORREZ, MUDALIAR, SUNDER · 1994 to 2022
$11.4M
NIDDM PRIMARY PREVENTION TRIALU01DK048412 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VENDITTI, ELIZABETH MARY · 1994 to 2021
$11.4M
PRIMARY PREVENTION TRIALU01DK048387 · NIDDK · MEDSTAR RESEARCH INSTITUTE · PI MAGEE, MICHELLE FISCHMANN · 1994 to 2022
$11.1M
TITLE OMITTEDU01DK048349 · NIDDK · YESHIVA UNIVERSITY · PI CRANDALL, JILL P · 1994 to 2021
$11.0M
University of Colorado Anschutz Medical Campus DRCP30DK116073 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI LORI SUSSEL · 2020 to 2026
$10.8M
PRIMARY PREVENTION TRIALU01DK048443 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI WATSON, KAROL E · 1994 to 2021
$10.2M
Post-DPP Follow-up StudyU01DK048375 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI DABELEA, DANA · 1994 to 2022
$10.0M
Post-Diabetes Prevention Program (DPP)U01DK048381 · NIDDK · UNIVERSITY OF CHICAGO · PI EHRMANN, DAVID A · 1994 to 2021
$9.6M
CSRD VA IK2 CX001907NIDDK NIH HHS P30 DK111022NIDDK NIH HHS P30 DK116073NIDDK NIH HHS U01 DK048339NIDDK NIH HHS U01 DK048349NIDDK NIH HHS U01 DK048375NIDDK NIH HHS U01 DK048380NIDDK NIH HHS U01 DK048381NIDDK NIH HHS U01 DK048387NIDDK NIH HHS U01 DK048397NIDDK NIH HHS U01 DK048400NIDDK NIH HHS U01 DK048404NIDDK NIH HHS U01 DK048407NIDDK NIH HHS U01 DK048411NIDDK NIH HHS U01 DK048412NIDDK NIH HHS U01 DK048413NIDDK NIH HHS U01 DK048434NIDDK NIH HHS U01 DK048437NIDDK NIH HHS U01 DK048443NIDDK NIH HHS U01 DK048468NIDDK NIH HHS U01 DK048489
6 · The paper itself

Abstract

aimTo test whether diabetes genetic risk modifies the association of successful lifestyle changes with incident diabetes. MATERIALS AND

methodsWe studied 823 individuals randomized to the intensive lifestyle intervention (ILS) arm of the Diabetes Prevention Programme who were diabetes-free 1 year after enrolment. We tested additive and multiplicative interactions of a 67-variant diabetes genetic risk score (GRS) with achievement of three ILS goals at 1 year (≥7% weight loss, ≥150 min/wk of moderate leisure-time physical activity, and/or a goal for self-reported total fat intake) on the primary outcome of incident diabetes over 3 years of follow-up.

resultsA lower GRS and achieving each or all three ILS goals were each associated with lower incidence of diabetes (all P < 0.05). Additive interactions were significant between the GRS and achievement of the weight loss goal (P < 0.001), physical activity goal (P = 0.02), and all three ILS goals (P < 0.001) for diabetes risk. Achievement of all three ILS goals was associated with 1.8 (95% CI 0.3, 3.4), 3.1 (95% CI 1.5, 4.7), and 3.9 (95% CI 1.6, 6.2) fewer diabetes cases/100-person-years in the first, second and third GRS tertiles (P < 0.001 for trend). Multiplicative interactions between the GRS and ILS goal achievement were significant for the diet goal (P < 0.001), but not for weight loss (P = 0.18) or physical activity (P = 0.62) goals.

conclusionsGenetic risk may identify high-risk subgroups for whom successful lifestyle modification is associated with greater absolute reduction in the risk of incident diabetes.

Indexed as

Diabetes Mellitus, Type 2Life StyleExerciseHumansRisk FactorsWeight Loss

Identifiers

PMID33394545
PMCPMC8852694
OpenAlexW3119810279

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.